Pharnext 2019 Universal Registration Document Approved by AMF

PARIS, France, 08:30 a.m. CET, November 10, 2020 - Pharnext SA (FR0011191287 - ALPHA), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence ("Company") using its PLEOTHERAPY(TM) platform, today announced that its 2019 Universal Registration Document has been approved by the Autorité des Marchés Financiers (AMF) on November 9, 2020 under number N° R. 20-029.


The Universal Registration Document is available to the public, in English only, on Pharnext website at www.pharnext.com, under Investors/Regulated Information and also on the AMF website at www.amf-france.org. Copies of this Universal Registration Document are available free of charge from Pharnext (46, rue Saint-Lazare 75009 Paris).


About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development.